Lisata Therapeutics Inc. (LSTA)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.45 |
Market Cap | 21.41M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.51 |
PE Ratio (ttm) | -1.02 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.95 |
Volume | 13,830 |
Avg. Volume (20D) | 43,445 |
Open | 2.55 |
Previous Close | 2.61 |
Day's Range | 2.47 - 2.62 |
52-Week Range | 2.19 - 4.20 |
Beta | undefined |
About LSTA
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfun...
Analyst Forecast
According to 1 analyst ratings, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 488.24% from the latest price.
Why Price Moved
News

2 weeks ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses recent pancreatic cancer trial milestones – ICYMILisata Therapeutics Inc (NASDAQ:LSTA) joined Proactive to discuss the latest updates from the compay's pancreatic cancer trials. The company recently announced preliminary results from its Phase 2ASCE...

2 weeks ago · proactiveinvestors.com
Lisata Therapeutics and WARPNINE unveil positive preliminary results from pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE have announced promising preliminary results from their Phase 1b/2a iLSTA trial, which is evaluating Lisata's investigational drug certepetide in com...

2 weeks ago · proactiveinvestors.com
Lisata Therapeutics unveils encouraging preliminary data from Phase 2 pancreatic cancer trialLisata Therapeutics Inc (NASDAQ:LSTA) has reported encouraging preliminary data for Cohort A of its ongoing ASCEND Phase 2 trial. The trial, conducted across 25 sites in Australia and New Zealand, is ...

2 months ago · proactiveinvestors.com
Lisata Therapeutics advances certepetide with trial enrollment milestone and new diagnostic partnershipLisata Therapeutics Inc (NASDAQ:LSTA) shares were reacting positively this week after the company announced further developments for its lead investigational drug candidate, certepetide. The company ...

2 months ago · proactiveinvestors.com
Lisata Therapeutics completes patient enrollment for CENDIFOX trialLisata Therapeutics Inc (NASDAQ:LSTA) announced that it has completed patient enrollment in all three cohorts of its Phase 1b/2a CENDIFOX trial evaluating the safety and efficacy of Lisata's investiga...

2 months ago · proactiveinvestors.com
Lisata Therapeutics and Kuva Labs to collaborate on cancer imaging solutionLisata Therapeutics Inc (NASDAQ:LSTA) has announced a collaboration and license agreement with Kuva Labs, a wholly owned subsidiary of Mi2 Holdings. The clinical-stage pharmaceutical firm said the agr...

2 months ago · proactiveinvestors.com
Lisata Therapeutics named ‘Specialized BioTherapeutics Company of the Year' at 2024 BioTech Breakthrough AwardsLisata Therapeutics Inc (NASDAQ:LSTA) has been awarded the title of ‘Specialized BioTherapeutics Company of the Year' at the 2024 BioTech Breakthrough Awards. The company said it was recognized for it...

2 months ago · proactiveinvestors.com
Lisata Therapeutics CEO discusses pancreatic cancer trial progress and new collaborations - ICYMILisata Therapeutics Inc (NASDAQ:LSTA) CEO David Mazzo joined Proactive to talk about the latest updates on its clinical trials and its third quarter financial performance. Mazzo highlighted advancemen...

3 months ago · seekingalpha.com
Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call TranscriptLisata Therapeutics, Inc. (NASDAQ:LSTA ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, C...

3 months ago · proactiveinvestors.com
Lisata Therapeutics advances clinical trials in Q3 ahead of 'data-rich' 2025Lisata Therapeutics Inc (NASDAQ:LSTA) reported significant advancements across its clinical portfolio in the third quarter, with multiple key data readouts projected over the next 18 months. Lisata's ...